Take a look back at this week's top stories.
By Hindi Stohl, MD, JD, James M. Shwayder, MD, JD
This month's Legally Speaking column delves into a case regarding shoulder and abdominal dystocia during a vaginal delivery for fetal hydrops.
By Lindsey Carr, Editor
Alabama’s attorney general retracted comments he made last week suggesting criminal prosecution for women taking abortion pills for pregnancy termination. He is now saying that only providers who prescribe the pills could be prosecuted.
By Lindsey Carr, Editor
If approved, DARE-HRT1 would become the first FDA-approved monthly intravaginal ring to deliver both estrogen and progestin hormone therapy.
By Lindsey Carr, Editor
Findings from a study in JAMA Network Open reveal valuable insight into the way cannabis legalization has impacted the perceptions of pregnant women who use cannabis in the US.
By Lindsey Carr, Editor
A new study in Menopause found body dissatisfaction to be a primary cause of eating disorders, especially during perimenopause.
By John Jesitus
Women on Medicaid with opioid use disorder (OUD) who use medications for opioid use disorder (MOUD) are more likely to use contraception and to undergo female sterilization than peers not prescribed MOUD, according to a study in Contraception.
By Lindsey Carr, Editor
The findings indicate a previously confirmed notion that COVID-19 vaccination does not impact pregnancy outcomes in couples experiencing infertility.
See you next week!
FDA approves Visby’s test for at-home STI identification
Published: March 28th 2025 | Updated: March 28th 2025The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.
Read More